| abstract |
REFERS TO COMPOUNDS OF FORMULA (ID) WHERE R1 IS ARYL OR HETEROARYL OPTIONALLY SUBSTITUTED BY C1-C5 ALKYL, C2-C5 ALKENYL, C2-C5 ALKINYL, AMONG OTHERS; R2 AND R3 ARE EACH C1-C5 ALKYL OPTIONALLY SUBSTITUTED WITH HYDROXY, C1-C5 ALCOXY, C1-C5 ALKYLTIO; R4 IS C1-C5 ALKYL, C2-C5 ALKYL, C2-C5 ALKYL, OPTIONALLY SUBSTITUTED WITH C1-C3 ALKYL, HYDROXY, HALOGEN, OXO; R5 IS HETEROARYL, OPTIONALLY SUBSTITUTED WITH HETEROCICLYLCARBONYL, AROYL, AMINOCARBONYL, AMONG OTHERS; R6 IS H, C1-C8 ALKYL, C2-C8 ALKENYL, AMONG OTHERS OPTIONALLY SUBSTITUTED WITH C1-C5 ALKYL, C2-C5 ALKYL, C2-C5 ALKYL, AMONG OTHERS. PREFERRED COMPOUNDS ARE: 1,1,1-TRIFLUORO-5-METOXY-4-METHYL-4-PHENYL-2-QUINOLIN-4-ILMETHYLPENTAN-2-OL; 5,5,5-TRIFLUORO-2-METHYL-2-PHENYL-4-QUINOLIN-4-ILMETHYLPENTAN-1,4-DIOL, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION AND A PREPARATION PROCEDURE. THESE COMPOUNDS ARE MODULATORS OF THE GLUCOCORTICOID RECEPTOR, BEING USEFUL FOR THE TREATMENT OF PULMONARY, RHEUMATIC, ALLERGIC, KIDNEY, HEPATIC, CARDIOVASCULAR, NEUROLOGICAL, TYPE I DIABETES, DIABETES, DIABETES, DIABETES, DIABETES, DIABETES, DIABETES TYPE I, and II |